14-3-3 σ and checkpoint with forkhead and ring finger (CHFR) methylation in serum in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations

被引：0
|
作者：
Reguart, N.
Porta, R.
Provencio, M.
Cardenal, F.
Cuello, M.
Ramirez, J. L.
Mayo, C.
Lianes, P.
Taron, M.
Rosell, R.
机构：
[1] Hosp Badalona Germans Trias & Pujol, ICO, Badalona, Spain
[2] Hosp Josep Trueta, ICO, Girona, Spain
[3] Clin Puerta del Hierro, Madrid, Spain
[4] Hosp Duran & Reynals, ICO, Barcelona, Spain
[5] Hosp Mataro, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7600
引用
收藏
页数：2
相关论文
共 50 条
  • [1] 14-3-3σ and checkpoint with forkhead and ring finger (CHFR) methylation in serum in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (pts) with EGFR mutations
    Fernanda, S.
    Ramirez, J. L.
    Reguart, N.
    Porta, R.
    Provencio, M.
    Cardenal, F.
    Cuello, M.
    Lianes, P.
    Taron, M.
    Rosell, R.
    EJC SUPPLEMENTS, 2007, 5 (04): : 366 - 366
  • [2] AXL MRNA OVEREXPRESSION CORRELATES WITH LUNG METASTASES IN ERLOTINIB-TREATED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (P) WITH EGFR MUTATIONS
    Costa, C.
    Gimenez-Capitan, A.
    Mayo, C.
    Simonetti, S.
    Majem, M.
    Queralt, C.
    De Aguirre, I.
    Benlloch, S.
    Taron, M.
    Rosell, R.
    ANNALS OF ONCOLOGY, 2010, 21 : 128 - 128
  • [3] Survivin and CrkL expression in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations
    Molina, M. A.
    Simonetti, S.
    Quiroga, V.
    Viteri, S.
    Campelo, R. G.
    Sanchez, J.
    Benlloch, S.
    Aldeguer, E.
    Taron, M.
    Rosell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] MUTATIONS OF THE CATALYTIC SUBUNIT ALFA OF PI3K (PIK3CA) IN ERLOTINIB-TREATED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (P) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS
    Angel Molina, Miguel
    Gasco, Amaya
    Carcereny, Enric
    Javier Sanchez, Jose
    Bertran-Alamillo, Jordi
    Mayo, Clara
    Aldeguer, Erika
    Jimenez-Capitan, Ana
    Yeste, Zaira
    Costa, Carlota
    Benlloch, Susana
    Martinez, Alex
    Buges, Cristina
    Bosch, Joaquim
    Isla, Dolores
    Domine, Manuel
    Provencio, Mariano
    Sanchez Torres, Jose Miguel
    Camps, Carlos
    Taron, Miquel
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S980 - S981
  • [5] CUSTOMIZING ERLOTINIB IN METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (P) HARBORING EGFR MUTATIONS
    Sirera, R.
    Catot, S.
    Gonzalez-Larriba, J. L.
    Bover, I.
    Alonso, G.
    Valdivia, J.
    Ibeas, R.
    Lianes, P.
    Martinez del Prado, P.
    Rosell, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 90 - 90
  • [6] Aberrant DNA methylation in checkpoint with fork head associated domain and RING finger (CHFR) gene predicts better survival in non-small-cell lung cancer (NSCLC) patients (p) treated with docetaxel (doc)
    Fernanda Salazar-Zaffaroni, Maria
    Luis Ramirez-Serrano, Jose
    Santarpia, Mariacarmela
    De Aguirre-Egana, Itziar
    Sanchez Torres, Jose Miguel
    Sanchez Torres, Jose Miguel
    Moran, Teresa
    Taron, Miquel
    Rosell, Rafael
    CANCER RESEARCH, 2006, 66 (08)
  • [7] PRETREATMENT EGFR T790M MUTATION AND BRCA1 MRNA EXPRESSION IN ERLOTINIB-TREATED ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (P) WITH EGFR MUTATIONS
    Rosell, R.
    Molina, M. A.
    Costa, C.
    Bertran-Alamillo, J.
    Mayo, C.
    Moran, T.
    Viteri, S.
    Mendez, P.
    Benlloch, S.
    Taron, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 129 - 129
  • [8] CLINICAL OUTCOMES IN ERLOTINIB-TREATED PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) HARBORING VERY RARE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS
    Domingues, Pedro Masson
    Montella, Tatiane
    Baldotto, Clarissa Serodio
    Siqueira, Mariana
    Zukin, Mauro
    Ferreira, Carlos Gil
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S169 - S169
  • [9] The nicotinic acetylcholine receptor (nAChR) subunit α3 (CHRNA3) polymorphism in advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations treated with erlotinib
    Cardona, A.
    Ramirez, J. L.
    De Aguirre, I.
    Benlloch, S.
    Porta, R.
    Palmero, R.
    Cardenal, F.
    Moran, T.
    Taron, M.
    Rosell, R.
    EJC SUPPLEMENTS, 2009, 7 (02): : 512 - 512
  • [10] Mutations of EGFR (mEGFR) in tumor tissue and serum DNA from stage IV non-small-cell lung cancer (NSCLC) patients (p) prospectively treated with erlotinib
    Moran, Teresa
    Mayo, Clara
    Queralt, Cristina
    Molina, Miguel Angel
    Benlloch, Susana
    Quiroga, Vanessa
    Rolfo, Christian
    Cuello, Mauricio
    Carcereny, Enric
    Cardona, Andres Felipe
    Taron, Miquel
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S503 - S504
12345